-
Table of Content
-
Report Prologue
-
Market Introduction
-
Definition
-
Scope of the Study
- Research Objective
- Assumptions
- Limitations
-
Research Methodology
-
Introduction
-
Primary Research
-
Secondary Research
-
Market Size Estimation
-
Market Dynamics
-
Drivers
-
Restraints
-
Opportunities
-
Challenges
-
Macroeconomic Indicators
-
Technology Trends & Assessment
-
Market Factor Analysis
-
Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
-
Value Chain Analysis
-
Investment Feasibility Analysis
-
Pricing Analysis
-
Global Recombinant Vaccines Market, by Route of Administration
-
6.1 Introduction
-
Intramuscular and Subcutaneous Administration
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
6.3 Oral Administration
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
6.4 Other Routes of Administration
-
Global Recombinant Vaccines Market, by Type
-
Introduction
-
Subunit recombinant vaccines
-
• Market Estimates & Forecast, 2020–2027
-
Attenuated recombinant vaccines
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
7.4 Vector recombinant vaccines
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
Global Recombinant Vaccines Market, by Disease
-
Introduction
-
Pneumococcal Disease
-
• Market Estimates & Forecast, 2020–2027
-
Cancer
-
Hepatitis B
-
Influenza
-
8.6 HPV (Human papillomavirus)
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
8.7 DPT
-
8.8 Others
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
Global Recombinant Vaccines Market, by End-User
-
Introduction
-
Hospitals & Clinics
-
Pediatrics
-
Adults
-
9.5 Veterinary
-
• Market Estimates & Forecast, 2020–2027
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
9.5.1 Poultry
-
9.5.2 Livestock
-
• Market Estimates & Forecast, by Region/Country, 2020–2027
-
Others
-
10 Global Recombinant Vaccines Market, by Region
-
Introduction
-
Americas
-
• Market Estimates & Forecast, by Region, 2020–2027
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
• Market Estimates & Forecast, by End-User, 2020–2027
-
North America
-
• Market Estimates & Forecast, by Country, 2020–2027
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
• Market Estimates & Forecast, by End-User, 2020–2027
-
U.S.
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
• Market Estimates & Forecast, by End-User, 2020–2027
-
Canada
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
• Market Estimates & Forecast, by End-User, 2020–2027
-
South America
-
• Market Estimates & Forecast, by Type, 2020–2027
-
Europe
-
• Market Estimates & Forecast, by Region, 2020–2027
-
Western Europe
-
• Market Estimates & Forecast, by Country, 2020–2027
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
Germany
-
• Market Estimates & Forecast, by Type, 2020–2027
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
• Market Estimates & Forecast, by End-User, 2020–2027
-
France
- U.K.
- Eastern Europe
-
• Market Estimates & Forecast, by Type, 2020–2027
-
Asia Pacific
-
• Market Estimates & Forecast, by Country, 2020–2027
-
Japan
- China
- India
- Australia
- Republic of Korea
- Rest of Asia Pacific
-
• Market Estimates & Forecast, by Disease, 2020–2027
-
The Middle East & Africa
-
• Market Estimates & Forecast, by Region, 2020–2027
-
United Arab Emirates
- Saudi Arabia
- Oman
- Kuwait
- Qatar
- Rest of the Middle East & Africa
-
11 Company Landscape
-
Introduction
-
Market Share Analysis
-
Key Development & Strategies
- Key Developments
-
12 Company Profiles
-
Astellas Pharma Inc
- Company Overview
- Route of Administration Overview
- Financials
- SWOT Analysis
-
CSL Limited
- Company Overview
- Route of Administration Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
Emergent BioSolutions, Inc.
- Company Overview
- Route of Administration Overview
- Financial Overview
- Key Development
- SWOT Analysis
-
GlaxoSmithKline
- Company Overview
- Route of Administration/Business Segment Overview
- Financial Overview
- Key Development
- SWOT Analysis
-
Johnson & Johnson (U.S.)
- Company Overview
- Route of Administration Overview
- Financial overview
- Key Developments
-
Mitsubishi Tanabe Pharma Corporation
- Company Overview
- Route of Administration Overview
- Financial Overview
- Key Developments
-
Merck & Co., Inc.
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Pfizer, Inc..
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Sanofi Pasteur SA
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Serum Institute of India Pvt. Ltd
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Bavarian Nordic
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Mitsubishi Tanabe Pharma Corporation
- Overview
- Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
Daiichi Sankyo
-
12.13.1 Overview
-
Route of Administration Overview
- Financials
- Key Developments
- SWOT Analysis
-
13 MRFR Conclusion
-
Key Findings
- From CEO’s View Point
- Unmet Needs of the Market
-
Key Companies to Watch
-
Prediction of Pharmaceutical Industry
-
14 Appendix
-
List of Tables and Figures
-
LIST OF TABLES
-
Table 1 Recombinant Vaccines Industry Synopsis, 2020–2027
-
Table 2 Global Recombinant Vaccines Market Estimates and Forecast, 2020–2027, (USD Million)
-
Table 3 Global Recombinant Vaccines Market by Region, 2020–2027, (USD Million)
-
Table 5 Global Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
-
Table 6 Global Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
-
Table 7 Global Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
-
Table 8 North America Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
-
Table 9 North America Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
-
Table 10 North America Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
-
Table 11 US Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
-
Table 12 US Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
-
Table 13 US Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
-
Table 14 Canada Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
-
Table 15 Million)
-
Table 16 Canada Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
-
Table 17 Canada Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
-
Table 18 South America Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
-
Table 19 South America Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
-
Table 20 South America Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
-
Table 21 Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
-
Table 22 Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
-
Table 23 Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
-
Table 24 Western Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
-
Table 25 Western Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
-
Table 26 Western Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
-
Table 27 Eastern Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
-
Table 28 Eastern Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
-
Table 29 Eastern Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
-
Table 30 Asia Pacific Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
-
Table 31 Asia Pacific Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
-
Table 32 Asia Pacific Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
-
Table 33 Middle East & Africa Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
-
Table 34 Middle East & Africa Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million) LIST OF FIGURES
-
Figure 1 Research Process
-
Figure 2 Segmentation for Global Recombinant Vaccines Market
-
Figure 3 Segmentation Market Dynamics for Recombinant Vaccines Market
-
Figure 4 Global Recombinant Vaccines Market Share, by Type 2020
-
Figure 5 Global Recombinant Vaccines Market Share, by End-Users, 2020
-
Figure 6 Global Recombinant Vaccines Market Share, by Region, 2020
-
Figure 7 North America Recombinant Vaccines Market Share, by Country, 2020
-
Figure 8 Europe Recombinant Vaccines Market Share, by Country, 2020
-
Figure 9 Asia Pacific Recombinant Vaccines Market Share, by Country, 2020
-
Figure 10 Middle East & Africa Recombinant Vaccines Market Share, by Country, 2020
-
Figure 11 Global Recombinant Vaccines Market: Company Share Analysis, 2020 (%)
-
Figure 12 Astellas Pharma Inc: Key Financials
-
Figure 13 Astellas Pharma Inc: Segmental Revenue
-
Figure 14 Astellas Pharma Inc: Geographical Revenue
-
Figure 15 Emergent BioSolutions, Inc.. Key Financials
-
Figure 16 Emergent BioSolutions, Inc.: Segmental Revenue
-
Figure 17 Emergent BioSolutions, Inc.: Geographical Revenue
-
Figure 18 Pfizer, Inc.. : Key Financials
-
Figure 19 Pfizer, Inc.. : Segmental Revenue
-
Figure 20 Pfizer, Inc.. : Geographical Revenue
-
Figure 21 GlaxoSmithKline: Key Financials
-
Figure 22 GlaxoSmithKline: Segmental Revenue
-
Figure 23 GlaxoSmithKline: Geographical Revenue
-
Figure 24 Mitsubishi Tanabe Pharma Corporation : Key Financials
-
Figure 25 Mitsubishi Tanabe Pharma Corporation : Segmental Revenue
-
Figure 26 Mitsubishi Tanabe Pharma Corporation . Geographical Revenue
-
Figure 29 Bavarian Nordic. Key Financials
-
Figure 30 Bavarian Nordic. Segmental Revenue
-
Figure 31 Bavarian Nordic. Geographical Revenue
Leave a Comment